GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (NAS:MORF) » Definitions » Enterprise Value

Morphic Holding (Morphic Holding) Enterprise Value : $683.53 Mil (As of Apr. 26, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Morphic Holding Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Morphic Holding's Enterprise Value is $683.53 Mil. Morphic Holding's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-178.69 Mil. Therefore, Morphic Holding's EV-to-EBIT ratio for today is -3.83.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Morphic Holding's Enterprise Value is $683.53 Mil. Morphic Holding's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-177.60 Mil. Therefore, Morphic Holding's EV-to-EBITDA ratio for today is -3.85.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Morphic Holding's Enterprise Value is $683.53 Mil. Morphic Holding's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.52 Mil. Therefore, Morphic Holding's EV-to-Revenue ratio for today is 1,311.95.


Morphic Holding Enterprise Value Historical Data

The historical data trend for Morphic Holding's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding Enterprise Value Chart

Morphic Holding Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial 279.68 846.60 1,354.02 687.73 734.70

Morphic Holding Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 687.73 1,074.31 2,016.90 417.28 734.70

Competitive Comparison of Morphic Holding's Enterprise Value

For the Biotechnology subindustry, Morphic Holding's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morphic Holding's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Morphic Holding's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Morphic Holding's Enterprise Value falls into.



Morphic Holding Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Morphic Holding's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Morphic Holding's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Morphic Holding  (NAS:MORF) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Morphic Holding's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=683.526/-178.686
=-3.83

Morphic Holding's current Enterprise Value is $683.53 Mil.
Morphic Holding's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-178.69 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Morphic Holding's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=683.526/-177.595
=-3.85

Morphic Holding's current Enterprise Value is $683.53 Mil.
Morphic Holding's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-177.60 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Morphic Holding's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=683.526/0.521
=1,311.95

Morphic Holding's current Enterprise Value is $683.53 Mil.
Morphic Holding's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Morphic Holding Enterprise Value Related Terms

Thank you for viewing the detailed overview of Morphic Holding's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Morphic Holding (Morphic Holding) Business Description

Traded in Other Exchanges
Address
35 Gatehouse Drive, A2, Waltham, MA, USA, 02451
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Executives
William Devaul officer: General Counsel and Secretary C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Bruce Rogers officer: Chief Scientific Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Marc Schegerin officer: CFO and COO ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Praveen P. Tipirneni director, officer: President and CEO C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Farrell Robert E Jr officer: VP Finance and Ops, Secretary CAMBRIDGE DISCOVERY PARK, 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Joseph P Slattery director C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Timothy A Springer director, 10 percent owner 36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Peter Linde officer: Chief Medical Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE A2, WALTHAM ME 02451
Nisha Nanda director 281 TRESSER BOULEVARD, STAMFORD CT 06901
Amir Nashat director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p. director 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Vikas Goyal director C/O SR ONE, LTD., 161 WASHINGTON ST., SUITE 500, EIGHT TOWER BRIDGE, CONSHOHOCKEN PA 19428
Otello Stampacchia director 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199

Morphic Holding (Morphic Holding) Headlines

From GuruFocus